FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 360:192-193 January 8, 2009 Number 2 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Cheson, B. D. PubMed Citation

To the Editor: In their review of monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma (Aug. 7 issue),¹ Cheson and Leonard did not mention a potential cause of resistance to this treatment. Statins, by depleting cholesterol in the cell membrane, have been shown to diminish the antitumor effects of rituximab in vitro (as well as in a small exploratory study in vivo) by inducing conformational changes in CD20, resulting in reduced anti-CD20 binding.² It is plausible that statins also induce changes in other surface antigens and likewise reduce the antitumor effects of other monoclonal antibodies. Physicians should be aware of this . . . [Full Text of this Article]

This article has been cited by other articles:

• Ennishi, D., Asai, H., Maeda, Y., Shinagawa, K., Ikeda, K., Yokoyama, M., Terui, Y., Takeuchi, K., Yoshino, T., Matsuo, K., Hatake, K., Tanimoto, M. (2009). Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol 0: mdp490v1-mdp490 [Abstract] [Full Text]